KRW1,029,000.00
2.90% day before yesterday
Korea, Aug 22, 08:09 am CET
ISIN
KR7207940008
Symbol
207940
Index

SAMSUNG BIOLOGICS Stock price

KRW1,000,000.00
+0.00 0.00% 1M
+0.00 0.00% 6M
+51,000.00 5.37% YTD
+45,000.00 4.71% 1Y
+149,000.00 17.51% 3Y
+188,612.87 23.25% 5Y
+857,512.58 601.82% 10Y
+857,512.58 601.82% 20Y
Korea, Closing price Fri, Aug 22 2025
+0.00 0.00%
ISIN
KR7207940008
Symbol
207940
Index

Key metrics

Basic
Market capitalization
KRW72.4t
Enterprise Value
KRW72.2t
Net debt
positive
Cash
KRW1.6t
Shares outstanding
71.2m
Valuation (TTM | estimate)
P/E
55.3 | 53.7
P/S
14.4 | 12.6
EV/Sales
14.4 | 12.6
EV/FCF
186.6
P/B
6.2
Financial Health
Equity Ratio
62.9%
Return on Equity
9.9%
ROCE
11.5%
ROIC
9.8%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
KRW5.0t | KRW5.7t
EBITDA
KRW1.7t | KRW2.3t
EBIT
KRW1.6t | KRW1.7t
Net Income
KRW1.3t | KRW1.3t
Free Cash Flow
KRW386.8b
Growth (TTM | estimate)
Revenue
19.5% | 26.0%
EBITDA
23.2% | 68.0%
EBIT
22.8% | 30.8%
Net Income
25.0% | 22.3%
Free Cash Flow
-59.7%
Margin (TTM | estimate)
Gross
53.0%
EBITDA
33.3% | 40.1%
EBIT
32.3%
Net
25.6% | 23.1%
Free Cash Flow
7.7%
More
EPS
KRW18,067.0
FCF per Share
KRW5,435.2
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is SAMSUNG BIOLOGICS a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

SAMSUNG BIOLOGICS Stock Analysis

Unlock Scores for Free

Analyst Opinions

33 Analysts have issued a SAMSUNG BIOLOGICS forecast:

32x Buy
97%
1x Hold
3%

Analyst Opinions

33 Analysts have issued a SAMSUNG BIOLOGICS forecast:

Buy
97%
Hold
3%

Financial data from SAMSUNG BIOLOGICS

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
5,031,693 5,031,693
19% 19%
100%
- Direct Costs 2,367,014 2,367,014
13% 13%
47%
2,664,679 2,664,679
26% 26%
53%
- Selling and Administrative Expenses 818,759 818,759
25% 25%
16%
- Research and Development Expense 169,092 169,092
79% 79%
3%
1,676,828 1,676,828
23% 23%
33%
- Depreciation and Amortization 50,297 50,297
38% 38%
1%
EBIT (Operating Income) EBIT 1,626,531 1,626,531
23% 23%
32%
Net Profit 1,285,902 1,285,902
25% 25%
26%

In millions KRW.

Don't miss a Thing! We will send you all news about SAMSUNG BIOLOGICS directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.

Head office South Korea
CEO John Rim
Founded 2011
Website samsungbiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today